Kite is an industry leader in the emerging field of cell therapy, using a patient’s own immune cells to fight cancer. The Company has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on tumor type. Its most advanced candidate, axicabtagene ciloleucel (axi-cel), is a CAR-T therapy currently under priority review by the FDA with a target action date of November 29, 2017. It is expected to be the first to market as a treatment for refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL). Kite has additional candidates in the pipeline for both hematologic cancers and solid tumors.